
Acurx Eyes Single-Trial FDA Approval for Ibezapolstat
Following a July 13 regulatory meeting, the FDA signaled it may allow Acurx Pharmaceuticals to submit a New Drug Application for its antibiotic ibezapolstat based on a single Phase 3 clinical trial, provided the efficacy data proves robust enough to cover both acute treatment and the reduction of infection recurrence.

























